Prostate Cancer



Proclarix®: A New Blood Test for Assessing Prostate Cancer Risk

For Men with a PSA Level Between 2 and 10 ng/mL

What is Proclarix®?

Proclarix® is a next-generation blood test used alongside PSA testing to help assess your risk of prostate cancer.

By measuring tumour specific proteins in your blood, it provides a personalised risk score that helps your doctor decide whether further investigations, such as an MRI scan or biopsy, may be needed.

Understanding the PSA Blood Test

PSA is the standard blood test used to help assess the risk of prostate cancer, but PSA alone has limitations. It can be raised for reasons other than cancer (known as fault positives), which may lead to unnecessary MRIs and biopsies.

If your PSA is between 2 and 10 ng/mL, PSA alone cannot reliably tell whether prostate cancer is present.

Am I Eligible for Proclarix®?

You may be eligible if your PSA level is between 2 and 10 ng/mL

If your PSA falls between these levels, Proclarix® can help guide further investigation decisions.

Understanding Your Results

Your Proclarix® result is reported as a personalised risk score between 0% and 100%.

- Below 10%: Lower risk of clinically significant prostate cancer.
- 10% or above: Further investigation is recommended.

Ask About Proclarix® Today

If your PSA is between 2 and 10 ng/mL, or you are worried about your prostate cancer risk, ask your GP or consultant whether Proclarix® is right for you.

Proclarix® is CE-IVDR certified and included in EAU urology guidelines. For use under clinical supervision. Not currently available on the NHS.

v1.0 2026

Source Genomics

CAMBRIDGE CLINICAL LABORATORIES